Cardinal Health (CAH) Earnings Analysis
Cardinal Health (CAH) next reports earnings on 2026-08-11, consensus EPS 2.42 USD. Last quarter (2026-04-30) it beat with EPS 3.17 USD vs 2.79 USD est (+13.6%). It has beaten estimates in 7/7 recent quarters (100%). Trailing P/E 33.62.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CAH next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | 2.42 USD |
| Revenue estimate | 65.15B |
CAH earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 3.17 USD | 2.79 USD | +13.6% | Beat |
| 2026-02-05 | 2.63 USD | 2.34 USD | +12.4% | Beat |
| 2025-10-30 | 2.55 USD | 2.18 USD | +17% | Beat |
| 2025-05-01 | 2.35 USD | 2.17 USD | +8.3% | Beat |
| 2025-01-30 | 1.93 USD | 1.74 USD | +10.9% | Beat |
| 2024-11-01 | 1.88 USD | 1.62 USD | +16% | Beat |
| 2024-08-14 | 1.84 USD | 1.73 USD | +6.4% | Beat |
Beat rate: 7/7 (100%) over reported quarters with consensus data.
CAH valuation and analyst view
| Trailing P/E | 33.62 |
|---|---|
| Trailing EPS | 6.634 USD |
| Price / book | -18.30 |
| Dividend yield | 0.93% |
| Market cap | 52.63B |
| Analyst consensus | Buy (18 buy / 15 hold / 0 sell) |
| Avg price target | 261 USD |
Related research pages
Frequently asked questions
When is Cardinal Health (CAH)'s next earnings date?
Cardinal Health is next scheduled to report on 2026-08-11, with a consensus EPS estimate of 2.42 USD and revenue estimate of 65.15B.
Did CAH beat earnings last quarter?
In its 2026-04-30 report, CAH posted EPS of 3.17 USD versus a 2.79 USD estimate — a beat of 13.6%.
What is CAH's earnings track record?
Over the last 7 reported quarters with consensus data, CAH beat estimates 7 times (100%).
What is CAH's current P/E ratio and EPS?
CAH trades at a trailing P/E of 33.62 on trailing EPS of 6.634042553191489 USD.
What do analysts rate CAH?
Analyst consensus is "Buy" across 33 ratings (0 strong buy, 18 buy, 15 hold, 0 sell, 0 strong sell). Average 12-month price target: 261 USD.